Revised SPCs: Olumiant (baricitinib) Film-Coated Tablets – all strengths

Dose dependent increases in blood alanine transaminase and aspartate transaminase activity were reported in patients treated with baricitinib vs. placebo; and events of diverticulitis and gastrointestinal perforation have been reported in trials and post-marketing sources.

Source:

electronic Medicines compendium